Our R&D Power Bases

We decided to locate our main R&D centres in world-class scientific hubs to take advantage of the networking opportunities and to progress our external innovation philosophy within established scientific ecosystems. Our three main sites are connected as an ‘innovation grid’, sharing real-time information, allowing us to adapt and focus capabilities to maximize our search and evaluation strategies on a global scale.

In addition, we have R&D capabilities at the following locations :

 

  • Beijing, China : Created in Beijing in 2012, the Asia Group Drug Development is the platform in charge of clinical trial coordination in Asia.

    •  

  • Berlin, Germany : The Berlin site has expertise and responsibility for the radiopharmaceutical development of peptides and small molecules. These activities are focusing on the radiolabeling process development and validation, as well as the support of the clinical sites for the local preparation and pre-administration handling of the investigational radiolabeled products.

    •  

  • Dreux, France : R&D activities are focused on the Pharmaceutical Development of new specialty care products for Oncology and Rare Diseases. In addition, all the Clinical Supply Chain activities for all Ipsen clinical studies are performed in this site. Dreux also develops a key expertise in drug delivery systems (Novel Formulation Technologies). These highly innovative technologies are either early stage drug development enablers (e.g. intracellular delivery of peptides) or instrumental for Life Cycle Management of commercialized products, providing opportunities for new formulations (e.g. long acting or sustained-release formulations) or alternative routes of administration (oral or transdermal route for peptides).

    •  

  • Dublin, Ireland : As our center for the production and development of peptide active pharmaceutical ingredients (APIs), the site currently produces the APIs for both Somatuline® and Decapeptyl®. Ipsen in Dublin also has responsibility for the development of chemical process and analytical method activities of peptide and small molecule APIs.

    •  

  • Wrexham, UK : The R&D Pharmaceutical Development (Biologics) Department at our Wrexham site focuses on the development of novel products in Neuroscience including bioprocess, formulation, analytical functions, working alongside manufacturing operations for production and global distribution of Dysport®.

3

 

International R&D Centers

€265m

 

investment in R&D in 2017

R&D at a glance

Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines, establishing our leadership position in key therapeutic areas, ensuring sustainable lifecycle management and, most importantly, creating a company of inspiring people throughout our R&D organization.

Our R&D strategy

As a global biopharmaceutical company, with a focus on innovation and specialty care, we have the ambition to build a robust, valuable and sustainable portfolio of innovative medicines to meet our patient’s needs. Our R&D strategy is guided by our end goal to ensure that we bring innovative medicines to market as quickly as possible to address unmet patient needs in the areas of Oncology, Neuroscience and Rare Diseases.

Pipeline

Ipsen’s R&D has a valuable pipeline encompassing both lifecycle management of our well-established products and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.

Clinical Trials

Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core areas of focus. A global network of healthcare professionals help us test new treatments and ensure their efficacy and safety by conducting studies called clinical trials.We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, as well as a proven ability to bring new, life changing therapies successfully through clinical development.

Our R&D Specialisms

Ipsen has a leading-edge technological platform in toxins, in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of strong external partnerships in the field. With their unique properties, toxin molecules offer potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine.